Artizan Biosciences is creating a new class of transformative precision therapeutics that target and block the root causes of diverse, serious diseases triggered by intestinal inflammation. The company is backed by highly respected investors and governed by a prestigious board of directors with broad industry experience.
Using multi-modality approaches, Artizan corrects intestinal dysbiosis by neutralizing the core triggers of the inflammatory process.
Artizan’s proprietary drug discovery platform identifies and characterizes microbial drivers of disease within precise patient subsets in certain cancers and gastrointestinal, metabolic, autoimmune, and neurodegenerative diseases.
July 21, 2022
Artizan Biosciences Announces Multi-Year Research Collaboration with the University Medical Center Utrecht and Microviable Therapeutics SL
Research will leverage Artizan’s proprietary IgA-SEQ™ discovery platform to identify gut microbiota that may affect the safety and efficacy of immune checkpoint inhibitor therapies. (more…)
June 28, 2022
Artizan Biosciences Signs Lease at Winchester Works in New Haven
Winchester Office LLC announced today it has signed a lease with Artizan Biosciences at Winchester Works, a technology and life sciences building anchored by New Haven’s Science Park and located across the street from Yale’s Science Hill. (more…)
Artizan’s world-class biobanking program collects proprietary samples and clinical data from patients and healthy controls. These samples enable critical research into disease mechanisms and aid the development of potential treatments.